In a report released today, Edward Tenthoff from Piper Sandler reiterated a Buy rating on Aslan Pharmaceuticals (ASLN – Research Report), with a price target of $15.00. The company’s shares closed last Friday at $1.07.
According to TipRanks, Tenthoff is a 4-star analyst with an average return of 3.9% and a 34.20% success rate. Tenthoff covers the Healthcare sector, focusing on stocks such as Alnylam Pharma, Arrowhead Pharmaceuticals, and Opko Health.
Currently, the analyst consensus on Aslan Pharmaceuticals is a Strong Buy with an average price target of $15.67, a 1,371.36% upside from current levels. In a report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $17.00 price target.
See today’s best-performing stocks on TipRanks >>
ASLN market cap is currently $17.41M and has a P/E ratio of -0.33.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Aslan Pharmaceuticals (ASLN) Company Description:
Aslan Pharmaceuticals Ltd. is a clinical-stage oncology-focused biopharmaceutical company, which engages in the development of novel therapeutics. Its pipeline includes varlitinib, ASLAN003, ASLAN004, and ASLAN002. The firm’s portfolio focuses on validated growth pathways applied to new patient segments, novel immune checkpoints, and novel cancer metabolic pathways. The company was founded by Carl Aslan Jason Morton Firth, Mark McHale, and Jeffrey Tomlinson in 2010 and is headquartered in Singapore.
Read More on ASLN:
- ASLAN Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update
- Aslan Pharmaceuticals announces anticipated upcoming milestones
- Aslan Pharmaceuticals sees cash runway into 2H24
- Aslan Pharmaceuticals reports Q3 EPS (56c) vs. (78c) last year
- Aslan Pharmaceuticals to co-host KOL on atopic dermatitis treatment
